KN-01 is under clinical development by PendreaBio and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect KN-01’s likelihood of approval (LoA) and phase transition for Breast Cancer took place on 04 May 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 04 May 2021 increased KN-01’s LoA and PTSR for Liver Cancer, and increased LoA and PTSR for Pancreatic Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their KN-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

KN-01 overview

KN-01 (Ceramide NanoLiposome) is under development for the treatment of Rrelapsed and refractory acute myeloid leukemia (RR-AML), solid tumors including liver cancer, pancreatic cancer, androgen receptor negative prostate cancer and breast cancer. It is administered intravenously. The drug candidate is a liposomal formulation of ceramide. It is developed based on nanoLiposome technology.

PendreaBio overview

PendreaBio formerly Keystone Nano, is a healthcare service provider that manufactures and markets nanoscale products to chemicals and pharmaceuticals companies. The center offers nanoparticle surfaces with passive and active targeting strategies. Its products are used for the treatment of solid-tumor and non-solid-tumor cancers, chemical research, diagnostic imaging and biological investigations, among others. PendreaBio’s NanoJacket and NanoLiposomes technologies supports to improve the delivery of chemicals and pharmaceuticals. The center also caters to medical, scientific and industrial sectors. It partners with pharmaceutical, biotechnology companies and cancer institutions, among others. PendreaBio is headquartered in State College, Pennsylvania, the US.

Quick View KN-01 LOA Data

Report Segments
  • Innovator
Drug Name
  • KN-01
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: PendreaBio
Highest Development Stage
  • Phase I


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.